Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist

Cannabinoid receptor 2 agonists and inverse agonists are emerging as new therapeutic options for a spectrum of autoimmune-related disease. Of particular interest, is the ability of CB2 ligands to regulate microglia function in neurodegenerative diseases and traumatic brain injury. We have previously...

Descripción completa

Detalles Bibliográficos
Autores principales: Presley, Chaela, Abidi, Ammaar, Suryawanshi, Satyendra, Mustafa, Suni, Meibohm, Bernd, Moore, Bob M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506688/
https://www.ncbi.nlm.nih.gov/pubmed/26196013
http://dx.doi.org/10.1002/prp2.159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506688/
https://www.ncbi.nlm.nih.gov/pubmed/26196013
http://dx.doi.org/10.1002/prp2.159

Ejemplares similares